Welcome to our dedicated page for Compass Pathways Plc news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways Plc stock.
Compass Pathways plc (Nasdaq: CMPS) generates frequent news as it advances COMP360, its investigational synthetic psilocybin treatment, through late-stage clinical development for serious mental health conditions. The company focuses on treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), and its updates often highlight progress in these programs, regulatory interactions, and collaborations related to potential delivery models.
News items for CMPS commonly cover clinical trial milestones, such as Phase 3 results in TRD and the design and initiation of late-stage trials in PTSD. For example, Compass has reported achievement of the primary endpoint in its COMP005 Phase 3 trial in TRD and the U.S. Food and Drug Administration’s acceptance of an Investigational New Drug application for COMP360 in PTSD, enabling a Phase 2b/3 trial. Publications of clinical data in peer-reviewed journals, including results from a Phase 2 PTSD study, are also featured.
Investors and observers can also expect announcements about strategic collaborations with healthcare organizations and clinic networks. These collaborations, including those with Radial Health, Greenbrook Mental Wellness Centers, Hackensack Meridian Health, Reliant Medical Group, Journey Clinical, Mindful Health Solutions, and HealthPort, are described as helping to inform how investigational COMP360 treatment might be integrated into various care settings if approved.
Additional CMPS news includes financial results, participation in investor and healthcare conferences, and corporate governance developments such as board appointments. Together, these updates provide context on Compass Pathways’ clinical, regulatory, and operational progress as it pursues evidence-based innovation in mental health. Readers interested in CMPS can use this news feed to follow key developments in the company’s COMP360 programs and broader mental health biotechnology strategy.
Compass Pathways (Nasdaq: CMPS) exercised 35,059,448 outstanding warrants on February 26, 2026, generating approximately $200 million in proceeds. The company issued 15,160,619 ADSs and, to certain institutional investors, pre-funded warrants to purchase up to 19,898,829 ADSs. Compass intends to use these proceeds, plus ~$141 million from a Feb 20, 2026 public offering and existing cash, to fund COMP005 and COMP006 Phase 3 trials, a Phase 2b/3 COMP360 PTSD trial, commercial readiness, and working capital; combined funds are expected to fund operations into 2028.
Compass Pathways (Nasdaq: CMPS) will attend the TD Cowen 46th Annual Healthcare Conference in Boston from March 2-4, 2026 and will hold a fireside chat on March 3, 2026 at 10:30am ET. A live audio webcast will be available on the company Investors "Events" page, with replays accessible for 30 days.
Compass Pathways (Nasdaq: CMPS) priced a public offering of 17,500,000 ADSs at $8.00 each and pre-funded warrants for up to 1,250,000 ADSs at $7.9999. Underwriters have a 30-day option for up to 2,812,500 ADSs. The offering is expected to close on or about February 20, 2026, with gross proceeds of approximately $150.0 million.
According to the company, net proceeds will fund ongoing COMP005 and COMP006 Phase 3 trials, a Phase 2b/3 trial of COMP360 in PTSD, accelerate commercial readiness, and support working capital and general corporate purposes.
Compass Pathways (Nasdaq: CMPS) launched a proposed public offering of $150.0 million of American Depositary Shares (ADSs) and, for certain institutional investors, pre-funded warrants. The company also expects to grant underwriters a 30-day option to buy up to an additional $22.5 million of ADSs.
The offering is subject to market conditions and will be made from a shelf registration effective May 7, 2025; a preliminary prospectus supplement will be filed with the SEC.
Compass Pathways (Nasdaq: CMPS) reported that the Phase 3 COMP006 trial met its primary endpoint: two 25 mg doses of COMP360 produced a highly statistically significant -3.8 point MADRS improvement versus 1 mg at Week 6 (p<0.001).
Across COMP005 and COMP006, rapid onset from Day 1, durable responses in some participants through Week 26, a generally well-tolerated safety profile, and a planned NDA submission in Q4 were announced.
Compass Pathways (Nasdaq: CMPS) said it will release new clinical data from two ongoing Phase 3 trials of COMP360, its proprietary synthetic psilocybin, on February 17, 2026 at 6:30 am ET.
The company will disclose Part A and Part B results from COMP005 and Part A from COMP006, followed by a live audio webcast with management at 8:00 am ET; a replay will be available for 30 days.
Compass Pathways (Nasdaq: CMPS) announced the U.S. FDA has accepted its IND for COMP360 in PTSD, enabling initiation of a Phase 2b/3 (COMP202) trial with a 12-week blinded Part A and 40-week open-label Part B; the primary endpoint is change in CAPS-5 at Week 8. Compass said prior Phase 2 open-label PTSD data showed rapid, durable symptom improvement (published September 2025). The company also reviewed commercial readiness for COMP360 in TRD and disclosed planned data timing: second half of Q1 2026 for combined COMP006/COMP005 readouts and COMP006 Part B 26-week data expected early Q3 2026. Financially, Compass amended a Hercules loan to up to $150M with $50M drawn, extended interest-only through at least January 5, 2029, and extended maturity to January 5, 2031.
Compass Pathways (Nasdaq: CMPS) announced a strategic collaboration with Radial Health to explore integration of investigational COMP360 synthetic psilocybin treatment into Radial’s growing U.S. interventional psychiatry clinic network.
The agreement is Compass’s seventh strategic collaboration and will inform scalable delivery models for COMP360 if FDA approved. Radial operates across five states, offers virtual assessments nationwide, and was co-founded by executives with prior consumer-healthcare experience. The collaboration aims to identify operational and patient‑experience learnings to enable seamless integration at launch.
Compass Pathways (Nasdaq: CMPS) will host a webinar on January 7, 2026, 10:00–11:30 am ET to discuss commercial preparations for treatment-resistant depression (TRD) and planned late-stage clinical trials for post-traumatic stress disorder (PTSD).
Management and collaboration partners will cover commercial readiness, provider economics for multi-hour treatments, patient care pathways, and the emerging profile of COMP360 in TRD. The company will also outline the planned late-stage program for COMP360 in PTSD and include KOL and industry perspectives.
Speakers include Dr Gary Small, Dr Geoff Grammer, Myriam Barthes, and Dimitri Cavathas. A live audio webcast is available at https://lifescievents.com/event/q0v8tp3/, with a replay accessible for 30 days after the event.
Compass Pathways (Nasdaq: CMPS) management will participate in two December investor conferences: a fireside chat at the 8th Annual Evercore Healthcare Conference in Coral Gables, FL on December 2, 2025 at 10:00am ET, and a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York, NY on December 3, 2025 at 1:30pm ET.
A live audio webcast of both events will be available from the company’s Investors “Events” page, with replays accessible for 30 days after each event.